Form 8-K CTI BIOPHARMA CORP For: Dec 06

�

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

FORM 8-K

�

CURRENT REPORT

Pursuant to Section�13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2014 (December 6, 2014)

�

CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)

�

�

3101 Western Avenue, Suite 600

Seattle, Washington 98121

(Address of principal executive offices)

Registrants telephone number, including area code: (206)�282-7100

Not applicable

(Former name or former address, if changed since last report).

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

�

�

�

�

�

---

Item�7.01. Regulation FD Disclosure.

On December 6, 2014, CTI BioPharma Corp. (the Company) issued a press release entitled CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers. The full text of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On December 9, 2014, the Company issued a press release entitled CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells. The full text of such press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information provided pursuant to this Item�7.01 shall not be deemed filed for purposes of Section�18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing or other document filed by the Company pursuant to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document. The information provided pursuant to this Item�7.01 shall instead be deemed furnished.

�

Item�9.01. Financial Statements and Exhibits.

(d) Exhibits

�

�

�

�

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

�

�

�

---

EXHIBIT INDEX

�

�

�

�

Exhibit 99.1

CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates

Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers

-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related

Cancers, Including AML, MDS, CMML and CLL-

-Analysis Also Provides Scientific Basis for Pacritinibs Lack of Myelosuppression, a Unique

Attribute Among Agents in Development for Myelofibrosis-

SEATTLE, Wash., December�6, 2014CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 clinical development, demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. Researchers presented the findings from this analysis at the 56th�American Society of Hematology (ASH) Annual Meeting�and Exposition held December�6-9 in San Francisco, CA.

The kinome profile of pacritinib shown in this analysis highlights how pacritinib is different from other JAK inhibitors that are currently on the market and in development for myelofibrosis, said Srdan Verstovsek, M.D., Ph.D., Director, Clinical Research Center for MPNs at The University of Texas MD Anderson Cancer Center and principal investigator for the Phase 3 PERSIST-2 trial of pacritinib. One of the findings observed in clinical trials to date is the lack of myelosuppression seen with other treatments. Pacritinibs potent inhibition of FLT3, c-fms, IRAK1 and c-kit, all critical targets in hematologic malignancies, highlights its potential therapeutic utility in other indications, such as AML, MDS, CMML and CLL.

The in vitro profiling of pacritinib across a panel of kinases showed the inhibition of all members of the JAK/FLT pathways, with the exception of JAK1. The JAK/FLT pathways are frequently dysregulated in many types of cancers. Additionally, pacritinib was found to inhibit the kinases c-fms and IRAK1. Disruption in the c-fms and IRAK1 pathways have been indicated to be involved in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL). CTI believes the clinical efficacy and reduced myelosuppression seen in Phase 2 trials of pacritinib in patients with myelofibrosis is also likely attributable to this unique kinase inhibition profile.

These data not only demonstrate the unique attributes of pacritinib compared to other marketed agents or agents in development for the treatment of myelofibrosis, many of which have activity against JAK1, but also show the potential for broader use in other blood-related cancers, said Jack Singer, M.D., Executive Vice President, Global Medical and Translational Medicine at CTI and lead author of the analysis. We are excited to pursue additional indications, such as AML, MDS, CMML and CLL, all of which are currently being evaluated in Phase 2 clinical trials, so we can potentially offer these patients an effective and less toxic treatment option.

About the Analysis

The analysis was conducted to develop a comprehensive kinase profile of pacritinib and elucidate a potential mechanism for its lack of myelosuppression as seen in clinical trials. The kinome screening analysis was done against a 429 member kinase panel and demonstrated the inhibition of all members of the JAK/FLT pathways at low nanomolar concentrations (e.g., JAK2 IC₅₀ = 6.0 nM, FLT3 IC₅₀ = 14.8 nM) with the exception of JAK1, against which pacritinib was completely inactive at 100nM. Additionally, pacritinib was a potent inhibitor of other tyrosine kinases of interest, including c-fms (IC₅₀ = 39.5 nM) and other non-tyrosine kinases such as IRAK1 (IC₅₀ = 13.6 nM). The results showed that pacritinib has an unusual spectrum of activity compared to other JAK inhibitors, combining lack of suppression of JAK1 with suppression of inflammatory signaling through c-fms and IRAK1.

The poster for Abstract #1874: Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis is available at www.ctibiopharma.com.

�

---

�

About Pacritinib

Pacritinib is a next generation oral multikinase inhibitor with activity against JAK2 and FLT3, as well as other kinases. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.

Based on pacritinibs efficacy and tolerability profile demonstrated to date, CTI is pursuing a broad approach to advancing this therapy for patients with myelofibrosis by conducting two Phase 3 clinical trials: one in a broad set of patients without limitations on blood platelet counts, the PERSIST-1 trial, and the other in patients with low platelet counts, the PERSIST-2 trial. The PERSIST-1 trial has completed enrollment with top-line results expected in the first quarter of 2015. The PERSIST-2 trial is actively enrolling patients.

In�November 2013, CTI and Baxter International (Baxter) entered into a worldwide license agreement to develop and commercialize pacritinib. Under this agreement, CTI and Baxter will jointly commercialize pacritinib in the U.S., while Baxter has exclusive commercialization rights for all indications outside the U.S.

About CTI BioPharma

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTIs lead product candidate that is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.�Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTIs securities.�Such statements include, but are not limited to, statements regarding CTIs expectations with respect to the development of CTI and its product and product candidate portfolio, pacritinibs potential advantages over other treatments and its other expected therapeutic benefits, expectations with respect to potential milestone and royalty payments and the license agreement with Baxter, CTIs ability to achieve its objectives and projections, including that of reporting top line results for the PERSIST-1 trial in early 2015, advancing CTIs various clinical trials and evaluating and developing CTIs product candidates in other indications in the future.�Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the commencement or outcome of preclinical and clinical studies, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities or will not be in a position to submit regulatory submissions as or when projected, risks related to the costs of developing, producing and selling PIXUVRI, pacritinib and CTIs other product candidates, and other risks, including, without limitation, competitive factors, technological developments, and that CTI may not achieve previously announced goals and objectives as or when projected, as well as other risks listed or described from time to time in CTIs most recent filings with the�SEC on Forms�10-K, 10-Q and 8-K.�Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

Source: CTI BioPharma Corp.

# # #

Contacts:

Monique Greer

+1 206-272-4343

[email protected]

2

�

---

�

Ed Bell

+1 206-282-7100

[email protected]

In Europe: CTI Life Sciences Limited, Milan Branch

Laura Villa

+39 02 94751572

[email protected]

�

3

�

�

Exhibit 99.2

CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal

Mediated Resistance in FLT3-ITD Positive AML Cells

-Significant synergy resulted with combination treatment of pacritinib and cytarabine or a MEK inhibitor-

SEATTLE, Wash., December�9, 2014CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays. The findings from this study were presented by Dr.�Ceri Marrin, Consultant Haematologist, University Hospital of Wales at Cardiff University, during an oral presentation at the 56th�American Society of Hematology (ASH) Annual Meeting�and Exposition held December�6-9 in San Francisco, CA.

About 30 percent of patients with AML have a mutation in FLT3, a known poor prognostic factor, and an important target for drug development. Traditional FLT3 inhibitors are unable to kill FLT3 mutated cells when grown on stromal cells of the microenvironment, and this is believed to be an important resistance factor for other FLT3 antagonists. Stromal interaction confers protection through upregulation of alternative survival pathways including MEK and JAK2. The current data show that pacritinib is able to evade this mechanism of resistance, likely through its ability to suppress other signaling pathways, such as JAK2, said Alan Burnett, M.D., Past Professor and Head of Haematology, Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University. While the data indicates that pacritinib was able to suppress growth of AML cells as a single agent, the synergistic effect of treatment with pacritinib in combination with either cytarabine or a MEK inhibitor suggest interesting directions for future clinical evaluation.

This study provides further evidence that pacritinib inhibits signaling pathways that are important to a broad spectrum of blood-related cancers. We believe pacritinib has the potential to be a significant new treatment option for AML given its ability to target multiple pathways, including suppression of microenvironmental tumor interactions that are key to overcoming longer-term drug resistance in this disease, said James A Bianco, M.D., President and CEO of CTI. A Phase 2 trial in patients with relapsed AML and FLT3 mutations is currently underway and a first-line study in elderly patients with AML is expected to be initiated in the near future.

About the Analysis

The efficacy of pacritinib was assessed in 62 primary AML samples that either carried a mutation in FLT3 (FLT3-ITD) or had wild type FLT3. A MS5 stromal co-culture model was used to assess FLT3-ITD cells that are adherent to non-adherent to stroma. The results showed that FLT3-ITD cells were more sensitive to pacritinib treatment compared to wild type samples and retained sensitivity to pacritnib treatment after seven days of co-culture with MS5 stroma cells. Following seven days of treatment, stroma-adherent FLT3-ITD cells had sustained suppression of leukemic outgrowth at 14 days. To assess long-term suppression of growth, the CD34+38- FLT3-ITD subpopulation of cells, which have in vivo engrafting ability, a leukemic stem cell property, and correlate with risk of clinical relapse, were plated with MS5 stroma cells. Pacritinib treatment significantly reduced cobblestone area forming cell (CAFC) frequency at five weeks.

Leukemic cell signaling was measured by culturing FLT3-ITD cells on stroma in the presence of pacritinib for up to 24 hours. Activity of the p-STAT5, JAK2, AKT and ERK signaling pathways was assessed by immunoblot and luminescent assays.

The authors concluded that pacritinib has the potential to overcome environmentally mediated drug resistance in FLT3 positive AML and demonstrated good synergy with cytarabine and a MEK inhibitor.

The presentation for Abstract #270: Pacritinib Suppresses Leukemic Outgrowth from FLT3-ITD Positive Stroma-Adherent Primary AML Cells is available at www.ctibiopharma.com.

�

---

�

About Pacritinib

Pacritinib is a next generation oral multikinase inhibitor with activity against JAK2 and FLT3, as well as other kinases. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.

Based on pacritinibs efficacy and tolerability profile demonstrated to date, CTI is pursuing a broad approach to advancing this therapy for patients with myelofibrosis by conducting two Phase 3 clinical trials: one in a broad set of patients without limitations on blood platelet counts, the PERSIST-1 trial, and the other in patients with low platelet counts, the PERSIST-2 trial. The PERSIST-1 trial has completed enrollment with top-line results expected in the first quarter of 2015. The PERSIST-2 trial is actively enrolling patients.

In�November 2013, CTI and Baxter International (Baxter) entered into a worldwide license agreement to develop and commercialize pacritinib. Under this agreement, CTI and Baxter will jointly commercialize pacritinib in the U.S., while Baxter has exclusive commercialization rights for all indications outside the U.S.

About CTI BioPharma

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTIs lead product candidate that is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.�Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTIs securities.�Such statements include, but are not limited to, statements regarding CTIs expectations with respect to the development of CTI and its product and product candidate portfolio, pacritinibs potential advantages over other treatments and its other expected therapeutic benefits (including the potential benefits when it is used in combination with either cytarabine or a MEK inhibitor), the potential application of pacritinib to treat AML, the expected initiation in the near future of a first line study of pacritinib in elderly patients with AML, expectations with respect to CTIs license agreement with Baxter, CTIs ability to achieve its objectives and projections (including that of reporting topline results for the PERSIST-1 trial in early 2015), advancing CTIs various clinical trials and evaluating and developing CTIs product candidates in other indications in the future.�Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the commencement or outcome of preclinical and clinical studies, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities or will not be in a position to submit regulatory submissions as or when projected, risks related to the costs of developing, producing and selling PIXUVRI, pacritinib and CTIs other product candidates, and other risks, including, without limitation, competitive factors, technological developments, and that CTI may not achieve previously announced goals and objectives as or when projected, as well as other risks listed or described from time to time in CTIs most recent filings with the�SEC on Forms�10-K, 10-Q and 8-K.�Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

Source: CTI BioPharma Corp.

# # #

Contacts:

Monique Greer

+1 206-272-4343

[email protected]

2

�

---

�

Ed Bell

+1 206-282-7100

[email protected]

In Europe: CTI Life Sciences Limited, Milan Branch

Laura Villa

+39 02 94751572

[email protected]

�

3

�

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tapestry, Inc. to Host FY24 Third Quarter Earnings Call
• Streamrecorder.io Review – The Ultimate Twitch VOD Downloader
• Energy for a Better Future: Entergy’s Environmental Stewardship